BrainRepair UG (haftungsbeschränkt)
Biowissenschaften & Gesundheitspflege
We are using stem cells from own cord blood to treat brain damage in ~30,000 children in need per year (EU) that have been granted Orphan Drug Designation by EC_EMA(EU/3/16/1744). The enormous potential of the treatment was shown in ~400 children worldwide in the absence of major adverse events. Our treatment of brain damage in newborn infants is ready for clinical use and will enjoy EU monopoly for 12 years. So far we invested 4.5m €.
Worldwide first Orphan Medicinal Product Designation by EMA for autologous cord blood stem cell product for the treatment of Periventricular leukomalacia in newborns (EU/3/16/1744)
Worldwide first Orphan Medicinal Product Designation by EMA for autologous cord blood stem cell product for the treatment of Neonatal encephalopathy in newborns (EU/3/16/1743)
First successful treatment of global hypoxic ischaemia and coma after cardiac arrest using autologous cord blood stem cells in a 2.5 years old boy with quadriplegia in 2009 (published 2013). Boy attends now primary school.
First successful treatment of traumatic stroke at birth using autologous cord blood stem cells in a 5 years old girl with hemiplegia in 2009 (published 2016). Girl now able to do 3 km city runs without orthesis and to play the piano.